BIOMAT Database Logo BIOMAT Database Logo

Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. 2009

David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, United States. david.l.gray@pfizer.com

Compounds that are both norepinephrine reuptake inhibitors (NRI) and 5-HT1(A) partial agonists may have the potential to treat neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD) and depression. Targeted screening of NRI-active compounds for binding to the 5-HT(1A) receptor provided a series of thiomorpholinone hits with this dual activity profile. Several iterations of design, synthesis, and testing led to substituted piperidine diphenyl ethers which are potent NRIs with 5-HT1(A) partial agonist properties. In addition, optimization of these molecules provided compounds which exhibit selectivity for NRI over the dopamine (DAT) and serotonin (SERT) reuptake transporters. Monoamine and 5-HT(1A) in vitro functional activities for select compounds from the developed piperidine diphenyl ether series are also presented.

UI MeSH Term Description Entries
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D010880 Piperidines A family of hexahydropyridines.
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004987 Ethers Organic compounds having two alkyl or aryl groups bonded to an oxygen atom, as in the formula R1–O–R2.
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014179 Neurotransmitter Uptake Inhibitors Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects. Reuptake Inhibitors, Neurotransmitter,Transmitter Uptake Inhibitors, Neuronal,Inhibitors, Neurotransmitter Uptake,Uptake Inhibitors, Neurotransmitter,Inhibitors, Neurotransmitter Reuptake,Neurotransmitter Reuptake Inhibitors
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D050486 Serotonin Plasma Membrane Transport Proteins Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of serotonergic neurons. They are different than SEROTONIN RECEPTORS, which signal cellular responses to SEROTONIN. They remove SEROTONIN from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. Regulates signal amplitude and duration at serotonergic synapses and is the site of action of the SELECTIVE SEROTONIN REUPTAKE INHIBITORS. Neurotransmitter Transport Proteins, Serotonin-Specific,Neurotransmitter Transporters, Serotonin-Specific,Serotonin Plasma Membrane Transporter Proteins,5-Hydroxytryptamine Plasma Membrane Transport Protein,5HT Transporter,Platelet Serotonin Transporter,SERT Proteins,SLC6A4 Protein,Serotonectin,Serotonin Transporter,Serotonin Transporter, Platelets,Sodium-Dependent Serotonin Transporter,Solute Carrier Family 6, Member 4 Protein,5 Hydroxytryptamine Plasma Membrane Transport Protein,Neurotransmitter Transport Proteins, Serotonin Specific,Neurotransmitter Transporters, Serotonin Specific,Platelets Serotonin Transporter,Serotonin Transporter, Platelet,Serotonin Transporter, Sodium-Dependent,Serotonin-Specific Neurotransmitter Transporters,Sodium Dependent Serotonin Transporter,Transporter, Sodium-Dependent Serotonin
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists.
January 2011, Bioorganic & medicinal chemistry letters,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.
February 2007, Bioorganic & medicinal chemistry letters,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
The future of 5-HT1A receptor agonists. (Aryl-piperazine derivatives).
January 1992, Progress in neuro-psychopharmacology & biological psychiatry,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
January 1994, The Journal of pharmacology and experimental therapeutics,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist.
June 2012, The AAPS journal,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
May 2011, Bioorganic & medicinal chemistry letters,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors.
February 2005, Bioorganic & medicinal chemistry letters,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.
December 2012, Bioorganic & medicinal chemistry letters,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
Molecular Modelling and Virtual Screening to Identify New Piperazine Derivatives as Potent Human 5-HT1A Antagonists and Reuptake Inhibitors.
May 2022, Combinatorial chemistry & high throughput screening,
David L Gray, and Wenjian Xu, and Brian M Campbell, and Amy B Dounay, and Nancy Barta, and Susan Boroski, and Lynne Denny, and Lori Evans, and Nancy Stratman, and Al Probert
Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases.
February 2010, Journal of medicinal chemistry,
Copied contents to your clipboard!